EQRx scores $500M to dri­ve its dis­rup­tive drug pric­ing mod­el and late-stage on­col­o­gy hope­fuls to mar­ket

Near­ly a year in­to its mis­sion of rewrit­ing the rules of drug pric­ing, EQRx has made a few key late-stage pick­ups to speed up its march to mar­ket. With the ball rolling faster than ex­pect­ed, in­vestors are jump­ing on board in droves — and EQRx will soon have to prove if its dis­rup­tive busi­ness mod­el holds wa­ter.

EQRx has bagged a $500 mil­lion Se­ries B — among the largest of its kind in re­cent bio­phar­ma his­to­ry — to con­tin­ue dri­ving its on­col­o­gy and in­flam­ma­to­ry can­di­dates to mar­ket, the com­pa­ny said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER